NASDAQ:NERV
Minerva Neurosciences Stock News
$2.39
-0.120 (-4.78%)
At Close: May 10, 2024
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
07:30am, Monday, 02'nd Aug 2021
WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervou
Sage Stock Declines on Late-Stage Depression Study Data
11:17am, Wednesday, 16'th Jun 2021
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
08:30am, Thursday, 10'th Jun 2021
WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat cen
Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
08:00am, Friday, 28'th May 2021
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat cent
Minerva Neurosciences (NERV) Enters Overbought Territory
07:31am, Wednesday, 19'th May 2021
Minerva Neurosciences (NERV) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?
09:01am, Monday, 17'th May 2021
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Best Penny Stocks to Buy During a Market Correction? Check These 4 Out
01:40pm, Thursday, 13'th May 2021
Looking for penny stocks to buy during a market correction? Check these 4 out for your watchlist The post Best Penny Stocks to Buy During a Market Correction?
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript
04:40pm, Wednesday, 12'th May 2021
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript
Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May
12:21pm, Wednesday, 12'th May 2021
Biotech penny stocks are heating up right now; here's 4 to watch The post Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May appeared first on Penny Stocks to Buy, Picks, News and Inform
Minerva (NERV) Soars on Promising Schizophrenia Study Data
11:16am, Wednesday, 12'th May 2021
Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study bo
Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
07:30am, Wednesday, 12'th May 2021
Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, im
NERV Stock: Over 25% Increase Pre-Market Explanation
04:53am, Wednesday, 12'th May 2021
The stock price of Minerva Neurosciences Inc (NASDAQ: NERV) increased by over 25% pre-market. This is why it happened.
WALTHAM, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous
Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021
05:10pm, Wednesday, 05'th May 2021
Management to host conference call Management to host conference call
Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock?
09:51am, Wednesday, 07'th Apr 2021
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
